Deverra Therapeutics

📍 Seattle, United States🗓 Founded 2020👥 14 employees💰 Last funded Aug 2024
Biotechnology🌐 deverratx.com
Website LinkedIn
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Deverra Therapeutics?
Deverra Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Deverra Therapeutics last raise funding?
The most recent investment in Deverra Therapeutics recorded on gritt.io was in August 2024.
When was Deverra Therapeutics founded?
Deverra Therapeutics was founded in 2020.
What industry is Deverra Therapeutics in?
Deverra Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Deverra Therapeutics based?
Deverra Therapeutics is headquartered in Seattle, United States.